SK Bioscience is accelerating the advancement of its production and process systems by appointing a production expert as a new executive to strengthen its global manufacturing competitiveness. The company aims to proactively establish a commercial production base for next-generation vaccines and new modality pipelines, while enhancing its manufacturing capabilities to support the expansion of global partnerships.
On December 18, SK Bioscience announced the appointment of Vice President Jongjun Cho, who has extensive experience in biopharmaceutical production and process technology at companies including LG Chem, as the new Head of Bulk Production.
Vice President Cho is a manufacturing expert who worked at LG Chem for about 20 years, overseeing commercial-scale biopharmaceutical production, new plant construction, and technology transfer for production processes. He managed bulk production of biopharmaceuticals based on microorganisms and animal cells at the Iksan and Osong plants, contributing to the stabilization of commercial production through technology transfer for new products and optimization of production processes. Notably, he led the Osong plant’s new bio facility construction project, executing the establishment of large-scale commercial production facilities and process scaling up. He also has experience responding to GMP (Good Manufacturing Practice) inspections by global regulatory agencies such as the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), the World Health Organization (WHO), and the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan.
Subsequently, at the biopharmaceutical CDMO (Contract Development and Manufacturing Organization) company Binex, he served as Head of Production at the Osong plant, overseeing contract manufacturing (CMO) projects for global pharmaceutical companies and managing production organizations. At GenMedicine, he was responsible for establishing a gene therapy production plant and setting up GMP systems, gaining experience in new modality production. Vice President Cho holds a bachelor's degree in Microbial Engineering from Konkuk University and a master's degree in Molecular Microbiology from Sungkyunkwan University.
Through this appointment, SK Bioscience plans to strengthen the stability of bulk production for biopharmaceuticals, including vaccines, as well as its ability to meet global regulatory requirements. The company will continue to advance its production and process platform by linking the Andong L HOUSE facility with the Songdo Global R&PD Center.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
